Zentalis Pharmaceuticals
ZNTL
99 hedge funds and large institutions have $79.7M invested in Zentalis Pharmaceuticals in 2025 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 36 increasing their positions, 33 reducing their positions, and 23 closing their positions.
24% more capital invested
Capital invested by funds: $64.5M → $79.7M (+$15.2M)
9% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 33
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
4.11% less ownership
Funds ownership: 77.28% → 73.17% (-4.1%)
15% less funds holding
Funds holding: 117 → 99 (-18)
42% less call options, than puts
Call options by funds: $65K | Put options by funds: $112K
78% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 23
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$2.42M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$1.25M |
| 3 |
Renaissance Technologies
New York
|
+$1.19M |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$604K |
| 5 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$517K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$3.86M |
| 2 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$2.41M |
| 3 |
AC
Almitas Capital
Santa Monica,
California
|
-$1.71M |
| 4 |
TCM
Tybourne Capital Management
Hong Kong
|
-$775K |
| 5 |
Goldman Sachs
New York
|
-$774K |
ZNTL Hedge Fund Activity: Q3 2025 in Review
99 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Zentalis Pharmaceuticals (ZNTL) for Q3 2025, worth a combined $79.7M — up 24% from $64.5M a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of ZNTL and 5 opened new positions — a net loss of 18 holders — while 33 trimmed existing stakes and 36 added.
The largest buyer was Citadel Advisors, adding an estimated $2.42M. The largest seller was Millennium Management, cutting an estimated $3.86M.
- 99 institutional investors held Zentalis Pharmaceuticals (ZNTL) as of Q3 2025, down from 117 in Q2 2025.
- Funds reported $79.7M of Zentalis Pharmaceuticals stock for Q3 2025, up 24% quarter-over-quarter.
- 5 funds opened new Zentalis Pharmaceuticals positions in Q3 2025 and 23 closed out, a net change of -18 holders.
- The largest Zentalis Pharmaceuticals buyer in Q3 2025 was Citadel Advisors, an estimated $2.42M added.
- The largest Zentalis Pharmaceuticals seller in Q3 2025 was Millennium Management, an estimated $3.86M sold.
Based on aggregated 13F filings for Q3 2025.